China Trials 2025

活動詳細資訊:

CHINATRIALS 2025 brings together global and regional leaders shaping the future of clinical research and biotech innovation, spanning early pipeline strategy, cross-border clinical development, and strategic partnerships. As a leading Asia-Pacific CRO and trusted global partner, Novotech will participate in two sessions on 13 November:

Novotech Participation (13 November):

• Advancing xDC Therapies in China: Accelerating Clinical Development & Global Strategy (11:45–12:30)

Moderator: Helen Jiang, Chief Medical Officer, Shanghai Best-Link Bioscience

Panelists: Jian Zhang, Director of Medical Oncology, Fudan University Shanghai Cancer Center; Anwen Xiong, Associate Chief Physician & Associate Professor, Shanghai East Hospital; Shuhang Wang, Associate Chief Physician, Cancer Hospital Chinese Academy of Sciences; Jing Li, Vice President, Mabpharm; Yun Tian, Director of Medical Service and Strategy, Novotech.

• Clinical Efficiency: Surviving a Changing Capital and Regulatory Environment (14:15–14:55)

Moderator: Irene Hong, Founding Partner, CEC Capital

Panelists: Anna French, Managing Partner, Qiming US; Andy Liu, General Manager, Novotech.

If you’d like to connect with our team in Shanghai, please schedule a meeting via the form on this page.